Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease

Am J Geriatr Psychiatry. 2010 Nov;18(11):973-82. doi: 10.1097/JGP.0b013e3181df48be.

Abstract

Objectives: Depression in the elderly might represent a prodromal phase of Alzheimer disease (AD). High levels of plasma amyloid beta-42 (Aβ42) were found in prestages of AD and also in depressed patients in cross-sectional studies. This study examined the association of emerging late-onset depression (LOD) and AD with plasma Aβ42 in a sample of never depressed and not demented persons at baseline.

Design: Prospective 5-year longitudinal study.

Participants: A community dwelling of older adults (N = 331) from the Vienna Transdanube Aging study.

Measurements: Laboratory measurements, cognitive functioning, and depressive symptoms were assessed at baseline, 2.5, and 5 years follow-ups.

Results: After exclusion of converters to AD, regression analysis revealed that higher plasma Aβ42 at baseline was a positive predictor for conversion to first episode of LOD. Independent of whether persons with mild cognitive impairment (MCI) at 2.5 years were included or excluded into regressions, higher plasma Aβ42 at baseline was a significant predictor for the development of probable or possible AD at 5 years. Higher conversion to AD was also associated with male gender but not with either higher scores on the Geriatric Depression Scale (GDS), with stroke or cerebral infarction nor apolipoprotein E ε4 allele. No association was found for an interaction between plasma Aβ42 levels and GDS.

Conclusions: Higher plasma Aβ42 at baseline predicted the development of first episode of LOD and conversion to probable or possible AD. Emerging depression as measured by scores on GDS at the 2.5-year follow-up, either alone or as an interaction factor with plasma Aβ42, failed to predict the conversion to AD at 5 years.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / blood
  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / genetics
  • Amyloid beta-Peptides / blood*
  • Apolipoprotein E4 / genetics
  • Cognition Disorders / blood
  • Cognition Disorders / diagnosis*
  • Cognition Disorders / genetics
  • Depressive Disorder / blood
  • Depressive Disorder / diagnosis*
  • Depressive Disorder / genetics
  • Disease Progression
  • Female
  • Geriatric Assessment / methods
  • Humans
  • Longitudinal Studies
  • Male
  • Peptide Fragments / blood*
  • Predictive Value of Tests
  • Risk Factors
  • Sex Characteristics

Substances

  • Amyloid beta-Peptides
  • Apolipoprotein E4
  • Peptide Fragments
  • amyloid beta-protein (1-42)